KV4.3 | Shal Related Potassium Channel Member 3

Family:
Potassium channels

Subgroups:
Shaker (KV1.1–KV1.8), Shab (KV2.1-KV2.2), Shaw (KV3.1–KV3.4), Shal (KV4.1–KV4.3), KQT like (KV7.1–KV7.5), Eag related (KV10.1-KV10.2), Erg related (KV11.1–KV11.3), Elk related (KV12.1)

Topology:
Contains six transmembrane domains (S1–S6), four single subunits form a pore, homotetramers and heterotetramers are possible.

KV4.3 Background Information

KV4.3, a voltage-activated A-type potassium ion channel, is prominent in the repolarization phase of the action potential and contributes to the cardiac transient outward potassium current (Ito1), the main contributing current to the repolarizing phase 1 of the cardiac action potential. Furthermore it contributes to ISA currents in neurons.

Gene:
KCND3

Human Protein:
UniProt Q9UK17-1, Q9UK17-2 (two different isoforms encoded by alternatively spliced transcript variants of the gene)

Tissue:
Heart, brain

Function/ Application:
repolarization of action potentials

Pathology:
Brugada Syndrome 9 (gain of function mutation), Spinocerebellar Ataxia 19, autosomal dominant inheritance, cerebellar atrophy, cognitive impairment, cogwheel rigidity, dysarthria

Interaction:
Homotetramer or heterotetramer with KCND1 and/or KCND2. Associates with the regulatory subunits KCNIP1, KCNIP2, KCNIP3 and KCNIP4, KCNE1, KCNE2, SCN1B, SRC, KCNAB1 and DLG1

Modulator:
4-AP, imipramine, E-4031, amitriptyline, disopyramide, XE 991 dihydrochloride

Assays:
Patch Clamp: whole cell

Recommended Reviews:
Gutman et al. (2005) International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev 57(4):473-508

Data and Applications

KV4.3 - Pharmacology of Metropolol Tartrate, using the CiPA Protocol

CiPA PE KV4.3 2icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384/768i) data and applications:
Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing KV4.3 current traces in response to the CiPA voltage step protocol, measured on the SyncroPatch 384PE using the whole cell patch methodology and single-hole chips. The IC50 value of Metropolol Tartrate was determined as 128 µM.

 

 

Cardiac Ion Channels - Pharmacology of Vandetanib

CiPA PE CE Pharmacology VandetanibIcon CE    CardioExcyte 96 and   icon pl   Patchliner data and applications:
Cells were kindly provided by Charles River and Cellular Dynamics.

The image on the left hand side displays the results of the blocking effect of Vandetanib on hERG, NaV1.5, CaV1.2 and KV4.3. The compound induced arrhythmia when iPSC-CM were exposed to a minimum concentration of 1 µM. Arrhytmic events were both detected in field potential recordings as well as in the impedance based contractility.

Cardiac Ion Channels - Pharmacology of Sotalol

CiPA PE CE Pharmacology SotalolIcon CE    CardioExcyte 96 and   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) data and applications:
Cells were kindly provided by Charles River and Cellular Dynamics.

The image on the left hand side displays the results of the blocking effect of Sotalol on hERG. The result is in good agreement with manual patch clamp data (Crumb et al., 2016). The compound induced arrhythmia when iPSC-CM were exposed to a minimum concentration of 10 µM. Arrhytmic events were both detected in field potential recordings as well as in the impedance based contractility measurements.

KV4.3 - Pharmacology of Quinidine

CiPA PE Kv4 3icon sp96    SyncroPatch 384/768 PE (a predecessor model of SyncroPatch 384/768i) data and applications:
Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing KV4.3 current traces in response to the CiPA voltage step protocol. Measured on the SyncroPatch 384PE using the whole cell patch methodology and multi-hole chips (4 holes per well), the success rate of valuable data for the analysis was  95.3%. The IC50 value of Quinidine was determined as 21.2 µM (Literature: 79.3 µM, Crumb et al., J Pharmacol Toxicol Methods. 2016).

KV4.3/KChIP2 - Dose-response curve of Flecanaide

icon sp96   170922 KV4.3 Data SyncroPatch384PESyncroPatch 384PE (a predecessor model of SyncroPatch 384i) data and applications:
Cells were kindly provided by Charles River.

Screenshots of the PatchControl 384 software showing KV4.3/KChIP2 current traces in response to a voltage step protocol and the corresponing current-voltage relationship plot. Using whole cell mode in combination with multi-hole chips (4 holes per well), stably transfected cells were measured on the SyncroPatch 384PE. The IC50 value of flecainide was determined as 28.3 µM which is in accordance to literature. The success rate of valuable data for the analysis was 100%. 

Application Notes

Cardiac Ion Channels - "Simultaneous Assessment of CiPA Stipulated Ion Channels on the SyncroPatch 384PE"

icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) application note   logo pdf   (1.3 MB)
Cells were kindly provided by Charles River.

Posters

2018 - High throughput automatic patch clamp: Applications for Safety Pharmacology

icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i) poster, JSPS Meeting 2018  logo pdf   (2.3 MB)

2017 - Cardiomyocytes in Voltage Clamp and Current Clamp by Automated Patch Clamp

icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) and   icon pl   Patchliner poster, BPS Meeting 2017  logo pdf   (1.7 MB)

2015 - High Throughput Automated Patch Clamp of Ion Channels Important in Cardiac Safety and Drug Discovery

icon sp96  SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) poster, Chantest Meeting 2015   logo pdf   (1.9 MB)

Presentations

2017 - HTS in Cardiac Safety

Icon CE   CardioExcyte 96 presentation (slide deck)   logo pdf   (4.0 MB)

2018 - HTS Phase I study: an update on progress of the CiPA Ion Channel Work Stream using the SyncroPatch 384PE and Patchliner

icon sp96   SyncroPatch 384PE (a predecessor model of the SyncroPatch 384i),   icon pl   Patchliner and   Icon CE   CardioExcyte 96 Oral Presentation

Presenter: 
Tim Strassmaier, Nanion Technologies Inc. USA
Source:
Webinar: "CiPA study: Bridging ion channel and myocyte data", September 12, 2018

Publications

2019 - A Kinetic Map of the Homomeric Voltage-Gated Potassium Channel (Kv) Family

 icon pl   Patchliner publication in Frontiers in Cellular Neuroscience (2019)

Authors:
Ranjan R., Logette E., Marani M., Herzog M., Tâche V., Scantamburlo E., Buchillier V., Markram H.

2015 - Novel screening techniques for ion channel targeting drugs

icon pl  Patchliner,   icon sp96   SyncroPatch 384PE (a predecessor model of SyncroPatch 384i) and   Icon CE   CardioExcyte 96 publication in Channels (2015)

Authors: 
Obergrussberger A., Stölzle-Feix S., Becker N., Brüggemann A., Fertig N., Möller C.

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.